These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 35227458)
1. Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease. Gandhi M; Tan RS; Lim SL; Rand K; Lam CSP; Luo N; Cheung YB Value Health; 2022 Mar; 25(3):451-460. PubMed ID: 35227458 [TBL] [Abstract][Full Text] [Related]
2. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577 [TBL] [Abstract][Full Text] [Related]
3. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set. Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730 [TBL] [Abstract][Full Text] [Related]
4. Valuation of EQ-5D-5L health states from cancer patients' perspective: a feasibility study. Chai Q; Yang Z; Liu X; An D; Du J; Ma X; Rand K; Wu B; Luo N Eur J Health Econ; 2024 Aug; 25(6):915-924. PubMed ID: 37837519 [TBL] [Abstract][Full Text] [Related]
5. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States. Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663 [TBL] [Abstract][Full Text] [Related]
6. The EQ-5D-5L Valuation Study in Egypt. Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590 [TBL] [Abstract][Full Text] [Related]
7. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA; Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214 [TBL] [Abstract][Full Text] [Related]
8. United States Valuation of EQ-5D-5L Health States Using an International Protocol. Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935 [TBL] [Abstract][Full Text] [Related]
9. Estimating an EQ-5D-5L Value Set for China. Luo N; Liu G; Li M; Guan H; Jin X; Rand-Hendriksen K Value Health; 2017 Apr; 20(4):662-669. PubMed ID: 28408009 [TBL] [Abstract][Full Text] [Related]
10. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis. Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745 [TBL] [Abstract][Full Text] [Related]
11. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery. Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N Patient; 2019 Aug; 12(4):383-392. PubMed ID: 30607809 [TBL] [Abstract][Full Text] [Related]
12. Valuation of EQ-5D-5L health states: a comparison of seven Asian populations. Wang P; Liu GG; Jo MW; Purba FD; Yang Z; Gandhi M; Pattanaphesaj J; Ahn J; Wong EL; Shafie AA; Busschbach JJ; Luo N Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):445-451. PubMed ID: 30523723 [No Abstract] [Full Text] [Related]
13. Less Is More: Cross-Validation Testing of Simplified Nonlinear Regression Model Specifications for EQ-5D-5L Health State Values. Rand-Hendriksen K; Ramos-Goñi JM; Augestad LA; Luo N Value Health; 2017; 20(7):945-952. PubMed ID: 28712624 [TBL] [Abstract][Full Text] [Related]
14. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians. Welie AG; Gebretekle GB; Stolk E; Mukuria C; Krahn MD; Enquoselassie F; Fenta TG Value Health Reg Issues; 2020 Sep; 22():7-14. PubMed ID: 31683254 [TBL] [Abstract][Full Text] [Related]
15. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis. Yang F; Wong CKH; Luo N; Piercy J; Moon R; Jackson J Eur J Health Econ; 2019 Nov; 20(8):1195-1206. PubMed ID: 31338698 [TBL] [Abstract][Full Text] [Related]
16. German Value Set for the EQ-5D-5L. Ludwig K; Graf von der Schulenburg JM; Greiner W Pharmacoeconomics; 2018 Jun; 36(6):663-674. PubMed ID: 29460066 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD). Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850 [TBL] [Abstract][Full Text] [Related]
18. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe. Golicki D; Jakubczyk M; Graczyk K; Niewada M Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586 [TBL] [Abstract][Full Text] [Related]
19. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set. Jyani G; Sharma A; Prinja S; Kar SS; Trivedi M; Patro BK; Goyal A; Purba FD; Finch AP; Rajsekar K; Raman S; Stolk E; Kaur M Value Health; 2022 Jul; 25(7):1218-1226. PubMed ID: 35779943 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan. Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K Value Health; 2016; 19(5):648-54. PubMed ID: 27565282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]